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Background: Single administration of intra-articular (IA) bupivacaine for pain relief after arthroscopic knee surgery is
effective, but its active duration and dose–response relationship is unclear. We conducted this meta-analysis to
summarize all published randomized controlled trials (RCTs), thus providing the most recent information on the
safety and efficacy of single-administration IA bupivacaine for pain relief after arthroscopic knee surgery, and to
determine whether a dose–response relationship exists.
Methods: A systematic electronic literature search (through April 2014) was conducted to identify those RCTs that
addressed the safety and efficacy of a single administration of IA bupivacaine for pain management after
arthroscopic knee surgery. Subgroup analysis was conducted to determine changes in visual analog scale (VAS)
scores at seven postoperative time points. Meta-regression and subgroup analyses were carried out to assess the
effects of various treatment factors on efficacy and to evaluate the dose–response relationship of bupivacaine.
Weighted mean differences or relative risks were calculated and pooled using a random-effects model.
Results: Twenty-eight trials involving 1,560 patients who underwent arthroscopic knee surgery met the inclusion
criteria. The trials were subject to medium risk of bias. VAS scores at 2, 4, 6, 12, and 24 h postoperatively were
significantly lower, the number of patients requiring supplementary analgesia was smaller, and the time to first
request for analgesia was longer in the IA bupivacaine group than in the placebo group. The analgesic effect of
single-administration IA bupivacaine may be associated with the effect of concomitant administration of epinephrine
and concentration of bupivacaine, and no dose–response relationship was identified. No significant difference in side
effects was detected between groups.
Conclusions: Current evidence shows that the use of single-administration IA bupivacaine is effective for postoperative
pain management in patients undergoing arthroscopic knee surgery, with satisfactory short-term safety. Low-dose
administration of IA bupivacaine 0.5% combined with epinephrine adjuvant in clinical practice should be performed.
Additional high-quality RCTs with longer follow-up periods are required to examine the safety of single-administration
IA bupivacaine.
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Arthroscopic knee surgery is one of the most common
orthopedic procedures performed in the outpatient set-
ting. Approximately 985,000 Americans underwent this
surgery in 2006, according to national estimates [1]. Al-
though knee arthroscopy causes less trauma than open
surgery, considerable postoperative pain can hinder a pa-
tient’s ability to participate in early rehabilitation and
affect the patient’s activity level and satisfaction. Patients
are usually discharged shortly after surgery and must
be provided with analgesia that is both safe and effect-
ive. Single intra-articular (IA) administration of local
anesthetic has been used to provide better analgesia
after arthroscopic knee surgery and to reduce con-
sumption and possible side effects of oral and intraven-
ous anesthetics.
Bupivacaine is often used for IA analgesia because of
its extended period of active effectiveness [1]. The analgesic
efficacy of IA bupivacaine, especially single-administration
bupivacaine, has been studied because its effect on post-
operative pain is conceptually simple. However, there are
conflicting reports on the efficacy of single-administration
IA bupivacaine. Despite reports supporting its use, the
results of a number of studies on the efficacy of single-
administration IA bupivacaine after arthroscopic knee sur-
gery have been equivocal [2,3].
The active duration of analgesia provided by a single
administration of IA bupivacaine is controversial as well.
In a review by Moiniche et al. [4], the reduction in pain
scores attributable to bupivacaine was short in duration,
and some studies [5,6] have demonstrated bupivacaine
to be superior to placebo for the first 2–4 h only. In con-
trast, other studies [7,8] showed bupivacaine to have a
longer analgesic effect than placebo and to be more effect-
ive in the first 24 h. In other studies [3,9], bupivacaine
dose and concentration were increased and augmented
with epinephrine to obtain a longer analgesic effect.
However, these findings were inconsistent, and a dose-
dependent relationship with effectiveness could not be
demonstrated [4]. Because of the simplicity and apparent
safety of the technique, it has gained widespread accept-
ance and use; nevertheless, the safety of IA bupivacaine
has also been questioned [10,11].
A recent meta-analysis by Wei et al. [1] indicated that
single-dose intra-articular bupivacaine is better than pla-
cebo at relieving pain after arthroscopic knee surgery.
However, the data from several RCTs were not included
in their analysis, and because VAS scores were acquired
at different time points in different included studies, the
results were pooled (i.e., VAS scores from 24 h postoper-
atively in one study and 48 h postoperatively in another
were combined). A high degree of heterogeneity com-
promised the power of their findings, and the contro-
versy surrounding active duration of analgesia providedby IA bupivacaine was ignored because of the lack of
distinction among VAS scores at different follow-up time
points. Finally, these researchers did not explore the ef-
fect of concentration, dose, and epinephrine use on the
effectiveness of IA bupivacaine and were thus unable to
determine whether the analgesic effect of IA bupivacaine
was dose-dependent.
Therefore, considering the methodological deficiencies
hindering exact interpretation in many studies, we con-
ducted a meta-analysis with the following goals: 1) to as-
sess the effectiveness and active duration of analgesia
provided by single-administration IA bupivacaine for pain
relief following arthroscopic knee surgery; 2) to evaluate
the effects of factors such as bupivacaine concentration
and supplemental epinephrine on the analgesic effect of
IA bupivacaine; 3) to determine whether there is a
dose–response relationship of IA bupivacaine and analgesic




This study was conducted in accordance with the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement [12], an additional
file shows this in more detail [see Additional file 1].
PubMed, the Cochrane Library, EMBASE, BIOSIS and
Ovid databases through April 10, 2014, were searched to
identify RCTs investigating a single administration of
bupivacaine and using a control group.
Study selection
Trials were included if they met the following criteria
for participants, interventions, comparisons, outcomes,
and study design (PICOS) criteria: 1) participants: demo-
graphically similar patients undergoing arthroscopic
knee surgery; 2) intervention: single administration of IA
bupivacaine after arthroscopic knee surgery; 3) compari-
son: placebo vs. no intervention; 4) outcomes: one or
more of the following outcomes reported: postoperative
VAS score, number of patients requiring supplementary
analgesia, time to first analgesic request, and side effects;
and 5) study design: RCT.
Data extraction
Articles were reviewed and cross-checked independently
by two authors (attending physicians in sports medi-
cine). The following data available for meta-analysis were
extracted: first author; country and year of publication;
number and characteristics of patients; doses, concentra-
tion, and administration method of bupivacaine; epi-
nephrine use and tourniquet use; type of anesthesia and
surgery; study design; and outcomes. These data were
entered into a standardized data-collection form that
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that would be presented in Table 1. If there were more
than two arms in a study, only data from the bupiva-
caine and placebo (or no-intervention) groups were ex-
tracted. A study was treated as two trials if it contained
two independent strata. Data were extracted from his-
tograms using Engauge Digitizer 4.0 (Free Software
Foundation, Boston, MA, USA) if not provided by an
article [13]. Data reported as median and range, size of
a trial, mean deviation, and standard deviation were
calculated using the method of Hozo [14].Quality assessment
The quality of each trial was evaluated by assigning a
modified Oxford Center for Evidence-Based Medicine
(OCEBM) grading-system score [15]. Each RCT was
independently assessed by two reviewers, who were
blinded to the basic information of each article, includ-
ing the names of the journal and the authors, to prevent
unnecessary bias. Disagreements were resolved by dis-
cussion, and a third reviewer’s opinion was asked for
when necessary.Statistical analysis
The outcome measures were pooled using a random-
effects model. For studies reporting multiple treatment
groups (such as bupivacaine at different doses), each
group was regarded as a single study in the meta-
analysis. Stratified analysis was conducted using VAS
scores at different postoperative time points (2, 4, 6, 12,
24, 48, and 72 h).
Heterogeneity was assessed with Cochran’s Q statistic
and quantified using the I2 statistic, which indicated the
proportion of variability across studies. Studies with an
I2 statistic of 25–50% are considered to have low hetero-
geneity, those with an I2 statistic of 50–75% to have
moderate heterogeneity, and those with an I2 statistic of
>75% to have a high degree of heterogeneity [16]. The
effect of individual studies on the pooled effect size was
assessed with a sensitivity analysis, in which the analysis
was repeated omitting one study at a time, to determine
the contribution of each study to the effect size.
Meta-regression models (P ≤ 0.1 was considered statis-
tically significant) and subgroup analyses were carried
out to assess the effect of various pre-specified treatment
factors (e.g., type of anesthesia, concentration of bupiva-
caine, epinephrine use, and tourniquet use) on treatment
efficacy [17]. In the dose–response analysis, we con-
ducted a meta-regression analysis of study-specific risk
ratios (RRs) by means of weighted linear regression [18]
to determine whether higher doses are associated with
increased treatment effect (i.e., reduction in number of
patients requiring supplementary analgesia).Publication bias occurs when there is systematic un-
derrepresentation of a given population in the published
literature. Potential publication bias was assessed by
visually inspecting a Begg funnel plot in which the risk
ratio reported for a study was plotted against the stand-
ard error. The presence of publication bias was also eval-
uated by using Begg and Egger tests [19,20].
A P value less than 0.05 was considered statistically
significant except where otherwise specified. All statistical
analyses were performed using Stata Statistical Software:
Release 11 (StataCorp LP, College Station, TX, USA).Results
Study selection
An initial database search using our search strategy
identified 201 RCTs, of which 150 were excluded for be-
ing duplicate studies or for various other reasons based
on the titles and abstracts. The remaining 51 full-text ar-
ticles were retrieved for more detailed evaluation, and 23
were subsequently excluded. Ultimately, 28 RCTs met
our inclusion criteria and were included in the present
meta-analysis (Figure 1).Study characteristics and quality assessment
Twenty-eight independent RCTs published between
1988 and 2012, including 1,560 individuals (786 in the
bupivacaine group and 774 in the placebo group), were
identified [2,3,5-7,9,21-43]. The characteristics and quality
assessment of the included studies are listed in Table 1.
An additional file shows study characteristics and quality
assessment in more detail [see Additional file 2].Primary outcome: VAS score for pain intensity
Twenty-one RCTs reported postoperative VAS scores
for pain intensity at different time points. Figure 2
shows the results of stratified analysis according to
VAS score at different follow-up time points from the
random-effects model. VAS scores were significantly
lower at 2, 4, 6, 12, and 24 h in the bupivacaine group
than in the placebo group. There were no significant
between-group differences in postoperative VAS score
at 48 h and 72 h. The association between VAS scores
and follow-up time points is presented in Appendix 1
under Association between SMD of the VAS scores and
follow-up time points.
To explore the effect of individual studies on the
pooled effect size, we then conducted a sensitivity ana-
lysis for postoperative VAS score by omitting one study
at a time and calculating the pooled standardized mean
differences (SMDs) for the remaining studies, and found
that there were no changes in the direction of effect
when any one study was excluded (Figure 3).
Table 1 Main characteristics of RCTs included in the meta-analysis




















Aasbo (1996) Norway 54 27/27 34/20 39 50 0.25 GA No 32 ± 20 28 ± 12 8 min
before RT
Yes Double-blind 5 (1/1/2/1)
RCT














Calmet (2004) Spain 40 20/20 NA NA 25 0.25 GA No NA Before RT Yes Double-blind 5(1/1/2/1)
RCT
Campo (2012) Netherlands 190 94/96 85/105 50.1 50 0.5 GA No 17 (8–40) 16 (4–36) Before RT Yes Double-blind 7(2/2/2/1)
RCT
















Eroglu (2010) Turkey 39 19/20 24/15 38.0 50 0.5 SA No 59 ± 12 52 ± 16 10 min
before RT
Yes RCT 5(2/2/0/1)












Izdes (2003) Turkey 60 30/30 35/25 39.7 62.5 0.25 GA No 33 ± 9 33 ± 9 10 min
before RT
Yes Double-blind 5(1/1/2/1)













Table 1 Main characteristics of RCTs included in the meta-analysis (Continued)
Marchal (2003) Spain 33 17/16 30/3 33.0 62.5 0.25 GA Yes 72.2 ± 52.9 67.5 ± 53.3 10 min
before RT
Yes Double-blind 5(1/1/2/1)
59.6 ± 26.8 61 ± 28.1 RCT










Australia 78 38/40 55/23 33.4 100 0.5 GA No 39.7 39.2 End of
surgery
NA Double-blind 6(1/2/2/1)
80 40/40 60/20 34.3 100 0.5 GA Yes 42.3 39.2 RCT
Raja (1992) USA 31 15/16 NA 45 50 0.25 SA Yes 90 ± 6 90 ± 6 Before RT Yes Double-blind 6(1/2/2/1)
RCT


























Tetzlaff (1999) USA 20 10/10 NA NA 150 0.25 GA Yes NA Before RT NA RCT 4(1/0/2/1)








BG: Bupivacaine group; F: Female; GA: General anesthesia; M: male; mOCEBM: Modified presentation of the Oxford Centre for Evidence-Based Medicine levels of evidence; NA: Not available; PG: Placebo group;













Figure 1 Flowchart showing the selection of studies for meta-analysis.
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Single-administration bupivacaine is associated with de-
creases in the number of patients requiring supplemen-
tary analgesia postoperatively and increases in the time
interval before the first request for any analgesic medica-
tion. An additional file shows secondary outcomes in
more detail [see Additional file 2].
Treatment factors affecting outcomes of IA bupivacaine
administration
We used meta-regression analysis to evaluate the effects
of various factors on outcomes and noted no association of
treatment effect with type of anesthesia (coefficient, −1.69;
P = 0.131; adjusted R2, 1.03%). We did, however, find associ-
ations with supplementation/no supplementation with
epinephrine (coefficient, −0.412; P = 0.07 < 0.1; adjusted
R2, 36.13%) and with concentration of bupivacaine (coeffi-
cient, −1.36; P = 0.10; adjusted R2, 48.43%), correlations
that may have clinical implications (Figure 4). An additional
file shows that effects of epinephrine use and concentration
of bupivacaine on the outcomes of IA administration of
bupivacaine in more detail [see Additional file 2].
Dose–response effect of bupivacaine
After evaluating the dose–response relationship using a
single meta-regression of bupivacaine dose for treat-
ment effect, we observed no significant relationshipsbetween reduction in the number of patients requiring
supplementary analgesia and increasing bupivacaine
dose (coefficient, −0.002; 95% confidence interval [CI] −0.009
to 0.005; P = 0.505) (Figure 5).Side effects
Side effects of nausea, vomiting, urinary retention, sed-
ation, headache, rash, and respiratory depression were eval-
uated in nine studies [2,23-30,34,35]. Nine studies provided
data on nausea, seven provided data on vomiting, three
provided data on urinary retention, two provided data on
sedation, two provided data on headache, two provided
data on rash, and one provided data on respiratory depres-
sion. Other complications, including postoperative brady-
cardia, postoperative hypotension, transient neurological
symptoms, and hemarthrosis, were also reported. Figure 6
shows that there was no significant difference in person-
time between participants who received IA bupivacaine
and those who received placebo (RR, 0.73; 95% CI, 0.47–
1.11; P = 0.142), and substantial heterogeneity was not seen
(P = 0.962; I2 = 0%).Publication bias
There was no potential publication bias among the
included trials (Egger’s test, P = 0.548; Begg’s test, P = 0.529,
Figure 7).
Figure 2 Forest plot of meta-analysis: VAS scores (0–10 points) representing postoperative pain intensity at different time points.
VAS: visual analog scale.
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The present meta-analysis of 28 RCTs [2,3,5-7,9,21-43]
evaluating the safety and efficacy of single-administration
IA bupivacaine in the management of pain after arthro-
scopic knee surgery has clearly shown that a singleadministration of IA bupivacaine is significantly better
than placebo and blank intervention at relieving pain.
Moreover, it may decrease the number of patients requir-
ing supplementary analgesia and prolong the time to first
request for analgesia. The most important findings of the
Figure 3 Influence of removing studies one by one on adjusted
effect estimates for 24-h-postoperative VAS scores. Circles are
effect estimates and horizontal dotted lines are 95% confidence
intervals for meta-analysis of the remaining studies; the vertical
center line is the pooled effect estimate for all studies.
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ciated with concomitant epinephrine and with concen-
tration of bupivacaine, 2) there was no dose–response
relationship of single-administration IA bupivacaine on
the analgesic effect, and 3) the use of single-administration
IA may not increase the prevalence of side effects during
short-term observation.
With regard to duration of analgesic effect, our meta-
analysis showed that single-administration IA bupivacaine
is effective for pain management for approximately 24 h
following arthroscopic knee surgery, which is consistent
with some previous studies [22,25,32,42]. However, most
of the RCTs [3,5,7,9,21,23,24,26-28,30,31,33,36-38,40,41]
included in this analysis reported either no effect or only a
very short (less than 12-hour) effect duration of single-
administration IA bupivacaine compared with placebo.
Various factors may have been responsible for the conflict-
ing results regarding the use of IA bupivacaine for painFigure 4 Meta-regression analyses of (A) use of supplemental epinep
corresponds to the weight of each study.control after arthroscopic knee surgery. Various acute or
chronic comorbidities might have had led to different
levels of pain tolerance [3], and the type of anesthetic
(general and/or spinal anesthetic) patients received [29]
might have affected the results because different amounts
of intraoperative opioids were used. The use of pre- and/
or perioperative opioids might also have influenced post-
operative analgesia [21]; for example, augmentation with
epinephrine might have slowed the release of analgesia
into the vascular system. In addition, postoperative
hemarthrosis may have increased the level of pain and
decreased the concentration of anesthetic within the
knee joint [43]. Concerns about the concentration and
duration of action of bupivacaine have also been re-
ported [41]. However, despite all these confounders, the
overall results of our meta-analysis suggest that the pa-
tients receiving IA bupivacaine had an analgesic effect
for 24 h postoperatively, and analysis of postoperative
time points revealed a positive correlation. (An additional
file shows that in more detail [see Additional file 3:
Figure S1]). In other words, the absolute difference of
VAS pain score (SMD) between the bupivacaine group
and the placebo group decreased as time progressed
postoperatively. Decreasing pain intensity over the
follow-up period could also explain this result.
In the present meta-analysis, we assessed the effects of
various pre-specified treatment factors on the treatment
efficacy of IA bupivacaine. According to our results, the
analgesic effect of IA bupivacaine appears to be associated
with epinephrine use and concentration of bupivacaine,
findings that may be applicable to clinical practice. These
findings are supported by some early research [5,9,29]. As
a concomitant treatment, epinephrine is considered to im-
prove the efficacy of a local anesthetic by slowing its re-
lease into the vascular system, and local presence of
epinephrine may alter the inflammatory process, thereby
interfering with the activation of the opiate receptors [5].hrine and (B) concentration of bupivacaine. Size of the circles
Figure 5 Dose–response effect of bupivacaine. Log of the
relative risk of number of patients requiring supplementary analgesia
in 19 trials of bupivacaine versus placebo by bupivacaine dose,
together with a summary random-effects meta-regression. The area
of each circle is inversely proportional to the variance of the log of
the relative-risk estimate.
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The concentration of bupivacaine also affected the results.
A higher concentration of bupivacaine traverses the syno-
vium more rapidly to reach the joint capsule, which is per-
forated by articular vessels and nerve endings [3]; indeed,
in the present analysis a 0.5% concentration of bupiva-
caine was associated with a better analgesic effect than
0.25%, which supports the use of a higher concentration
of bupivacaine. In general, the administration of IA 0.5%
bupivacaine augmented by epinephrine in clinical practice
may be advisable.
The present meta-analysis investigated whether the ef-
fectiveness of IA bupivacaine after arthroscopic knee
surgery was dose-dependent. Our results suggest that
there was no association between the reduction in num-
ber of patients requiring supplementary analgesia and
bupivacaine dose, a potentially valuable finding given
that high doses of IA bupivacaine may be associatedFigure 6 Forest plot of meta-analysis. Side effects.with adverse side effects. Recent studies have demon-
strated dose dependent chondrotoxic effects of bupiva-
caine in vitro as well as in vivo [45,46], suggesting that
low-dose IA bupivacaine is potentially the least harmful
strategy [47]. Despite quite strong evidence for chondro-
toxicity, the incidence of chondrolysis following IA ad-
ministration of bupivacaine in clinical practice seems to
be low or possibly underreported [48]. Given equal effi-
cacy for pain control after arthroscopic knee surgery
across doses and a dose–response relationship for chondro-
toxic effects, a clinical decision leaning toward low-dose
(50-mg) bupivacaine appears to be supported, although
the lowest effective bupivacaine dose has not yet been
identified.
Our meta-analysis revealed no significant difference in
the rate of side effects between the IA-bupivacaine
group and the placebo group. Consistent with a previous
review [1], this important finding establishes the safety
of IA bupivacaine during very short term observation.
Moreover, compared with continuous IA infusion of an-
algesics, which is associated with large effusion of the
surgical wound and direct access for infectious agents
with catheter placement, single-administration IA bupi-
vacaine maximizes the safety of postoperative pain relief
in the early postoperative period. Nevertheless, it should
be recognized that the follow-up period in the majority
of studies was not long enough to detect signs and
symptoms of infection. Although plasma levels were all
below reported toxic plasma bupivacaine concentrations
[49], data on cardiac and central nervous system toxicity
of megadose bupivacaine for assessment of long-term
safety are lacking. Further investigation of the long-term
safety of IA bupivacaine is therefore required.
The present study has some limitations that should be
taken into account. First, we acknowledge that the indi-
vidual studies included relatively small numbers of pa-
tients (n < 30 in three studies [30,37,40]) and that
overestimation of the treatment effect is more likely in
Figure 7 Tests for publication bias for relative risk of the
number of patients requiring supplementary analgesia.
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eity among the included trials. Lack of standardization
of IA-bupivacaine administration (e.g., with respect to
injection time) and differing study designs may have led
to heterogeneity and potentially affected our results. Fur-
thermore, side effects require some time to become ap-
parent, but none of our included studies had long
enough observation periods to accomplish this.
Conclusions
In conclusion, current evidence suggests that single-
administration IA bupivacaine is effective for pain relief
after arthroscopic knee surgery. Low-dose administra-
tion of IA bupivacaine 0.5% combined with epinephrine
may be advisable in clinical practice. However, because
the follow-up period in majority studies may not have
been of sufficient duration, more safety data during long-
term follow-up are required.
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